Current treatments for preventing thrombotic disease are still inconvenient and associated with a high risk of bleeding. Improved anticoagulant agents are therefore required. TB-402 is a monoclonal antibody (fully human IgG4-antibody) that targets factor VIII (FVIII) and represents a novel type of anticoagulant agent. In vitro, TB-402 only partially inhibits human FVIII even when TB-402 is in excess over FVIII. Preclinical studies confirmed this plateau inhibition and also established the antithrombotic efficacy of TB-402 (
Disclosure:Employment: S. Pakola, JM Stassen, and Desire Collen are employees of the sponsor of this trial, ThromboGenics. S. Glazer is an employee of the co-development partner for TB-402 development, BioInvent. Consultancy: P. Verhamme has provided consulting services for the Sponsor, ThromboGenics. Ownership Interests:; S. Pakola and JM Stassen own share options and no shares in sponsor, ThromboGenics. D Collen owns shares and share options in Sponsor, ThromboGenics. S. Glazer owns share options and no shares in co-development partner, BioInvent. Membership Information: Desire Collen.